Question 1

What is Solventum's EV/EBITDA ratio?

Accepted Answer

Solventum (SOLV) EV/EBITDA ratio is 6.8× as of June 5, 2026. The ratio is calculated by dividing enterprise value by trailing twelve-month EBITDA, using USD-normalised financials (IAS 21 exchange-rate translation for non-USD reporters).

Question 2

How is the EV/EBITDA ratio calculated?

Accepted Answer

EV/EBITDA = Enterprise Value ÷ Trailing Twelve-Month (TTM) EBITDA, where Enterprise Value = Market Capitalisation + Total Debt − Cash & Short-Term Investments. All inputs are sourced from audited GAAP/IFRS filings and translated to USD using period-end exchange rates so the multiple is comparable across companies and currencies.

Question 3

What is the EV/EBITDA ratio?

Accepted Answer

The EV/EBITDA ratio (the enterprise multiple) compares enterprise value (EV) to trailing twelve-month (TTM) EBITDA. EV is calculated as market capitalisation + total debt − cash & short-term investments. Because EV/EBITDA is capital-structure-neutral and ignores non-cash depreciation and amortisation, it is the standard multiple used in M&A and for cross-company or cross-border comparisons. Note: this calculation uses a simplified EV (minority interest and preferred equity excluded due to data availability), consistent with most public financial-data providers.

Question 4

What is a good EV/EBITDA ratio for Solventum?

Accepted Answer

Mature, cash-generative businesses commonly trade in the 8–12× EV/EBITDA range; higher-growth, asset-light companies often trade at 15–25×+. EV/EBITDA is most useful for comparing companies with different capital structures (debt levels) or tax regimes. For Solventum specifically, the relevant sector benchmark is the current sector median of 15.0×.

Question 5

Is Solventum's EV/EBITDA ratio high or low?

Accepted Answer

Solventum's EV/EBITDA ratio of 6.8× is below its own 5-year average of 9.4× and below the sector median of 15.0×. That places the current reading at the 21th percentile of its 10-year history. A higher multiple usually reflects stronger expected growth, lower perceived risk, or higher returns on capital; a lower multiple reflects the opposite.

Question 6

What is Solventum's historical EV/EBITDA ratio range?

Accepted Answer

In the available daily series, Solventum (SOLV) EV/EBITDA ratio has ranged from a low of 5.4× in 2026 to a high of 16.3× in 2025. The 5-year average is 9.4× and the 5-year median is 8.4×.

Question 7

What was Solventum's EV/EBITDA ratio in 2025?

Accepted Answer

Solventum (SOLV) EV/EBITDA ratio at the end of 2025 was 6.4×. Annual values reflect the multiple on the last trading day of each calendar year, using the trailing twelve-month EBITDA figure available at that date.

Question 8

Why does Solventum's EV/EBITDA ratio change over time?

Accepted Answer

Valuation multiples move with two inputs: the numerator (enterprise value, which tracks share price plus net debt) and the denominator (EBITDA). Share-price changes — driven by interest rates, earnings expectations, risk appetite, and broader market sentiment — typically dominate short-term moves, while changes in the underlying fundamental drive the longer-term trend. As a result, the ratio can rise during stock-price rallies even if the business itself has not become more valuable, and fall during sell-offs even when fundamentals are improving.


2025	$13.80B	$2.81B	6.4×	-5.9×	Dec 31, 2025
2024	$11.45B	$1.53B	12.2×	+2.4×	Dec 31, 2024
2023	$13.82B	$2.23B	9.8×	+3.3×	Dec 31, 2023
2022	$13.80B	$2.11B	6.6×	—	Dec 31, 2022


Align Technology (ALGN)	14.0×
Gilead Sciences (GILD)	13.9×
Labcorp Holdings (LH)	13.6×
Amgen (AMGN)	13.6×
Charles River (CRL)	13.2×
Regeneron Pharmaceuticals (REGN)	12.9×
GE HealthCare (GEHC)	12.9×
UnitedHealth Group (UNH)	12.7×
Pfizer (PFE)	12.4×
Henry Schein (HSIC)	12.0×
Medtronic (MDT)	11.7×
AptarGroup (ATR)	11.5×
Bristol-Myers Squibb (BMY)	11.5×
Zimmer Biomet Holdings (ZBH)	11.2×
Biogen (BIIB)	10.5×
HCA Healthcare (HCA)	10.0×
Molina Healthcare (MOH)	8.8×
DaVita (DVA)	8.5×
IQVIA (IQV)	8.2×
Incyte (INCY)	7.9×
Cigna (CI)	7.8×
Elevance Health (ELV)	6.8×
Novo Nordisk (NVO)	6.5×
Universal Health Services (UHS)	5.7×
Humana (HUM)	4.5×

EV/EBITDA for Solventum (SOLV)

EV/EBITDA daily chart for Solventum (SOLV)

Historical EV/EBITDA for Solventum (SOLV) from 2022 to 2025

About EV/EBITDA at Solventum (SOLV)

Solventum EV/EBITDA by Year

Solventum EV/EBITDA 2025: 6.4×

Solventum EV/EBITDA 2024: 12.2×

Solventum EV/EBITDA 2023: 9.8×

Solventum EV/EBITDA 2022: 6.6×

Sector peers by EV/EBITDA — chart

Sector peers by EV/EBITDA — table

Frequently asked questions

Solventum (SOLV) Key Financials

EV/EBITDA daily chart for Solventum (SOLV)

Historical EV/EBITDA for Solventum (SOLV) from 2022 to 2025

About EV/EBITDA at Solventum (SOLV)

Solventum EV/EBITDA by Year

Solventum EV/EBITDA 2025: 6.4×

Solventum EV/EBITDA 2024: 12.2×

Solventum EV/EBITDA 2023: 9.8×

Solventum EV/EBITDA 2022: 6.6×

Sector peers by EV/EBITDA — chart

Sector peers by EV/EBITDA — table

Frequently asked questions

+What is Solventum's EV/EBITDA ratio?

+How is the EV/EBITDA ratio calculated?

+What is the EV/EBITDA ratio?

+What is a good EV/EBITDA ratio for Solventum?

+Is Solventum's EV/EBITDA ratio high or low?

+What is Solventum's historical EV/EBITDA ratio range?

+What was Solventum's EV/EBITDA ratio in 2025?

+Why does Solventum's EV/EBITDA ratio change over time?

Solventum (SOLV) Key Financials